Juraj Velcicky

1.2k total citations
24 papers, 957 citations indexed

About

Juraj Velcicky is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Juraj Velcicky has authored 24 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Juraj Velcicky's work include Melanoma and MAPK Pathways (5 papers), Metal complexes synthesis and properties (4 papers) and Receptor Mechanisms and Signaling (4 papers). Juraj Velcicky is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Metal complexes synthesis and properties (4 papers) and Receptor Mechanisms and Signaling (4 papers). Juraj Velcicky collaborates with scholars based in Switzerland, United States and Germany. Juraj Velcicky's co-authors include Dale L. Boger, Hayato Ishikawa, Gregory I. Elliott, Hans‐Günther Schmalz, Younggi Choi, Roland Steiner, Thomas Wieder, Pius Loetscher, Roland Feifel and Aram Prokop and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Journal of Medicinal Chemistry.

In The Last Decade

Juraj Velcicky

24 papers receiving 940 citations

Peers

Juraj Velcicky
Frederick W. Goldberg United Kingdom
Darren McKerrecher United Kingdom
Andrea M. Zuhl United States
Jaclyn L. Henderson United States
Anne Mengel Germany
Jun‐ichi Haruta Japan
Andrew Madin United Kingdom
Etienne J. Donckèle Switzerland
Jenny Roy Canada
G.M. Robertson United Kingdom
Frederick W. Goldberg United Kingdom
Juraj Velcicky
Citations per year, relative to Juraj Velcicky Juraj Velcicky (= 1×) peers Frederick W. Goldberg

Countries citing papers authored by Juraj Velcicky

Since Specialization
Citations

This map shows the geographic impact of Juraj Velcicky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juraj Velcicky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juraj Velcicky more than expected).

Fields of papers citing papers by Juraj Velcicky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juraj Velcicky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juraj Velcicky. The network helps show where Juraj Velcicky may publish in the future.

Co-authorship network of co-authors of Juraj Velcicky

This figure shows the co-authorship network connecting the top 25 collaborators of Juraj Velcicky. A scholar is included among the top collaborators of Juraj Velcicky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juraj Velcicky. Juraj Velcicky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Velcicky, Juraj, Philipp Janser, Nina Gommermann, et al.. (2024). Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors. Journal of Medicinal Chemistry. 67(2). 1544–1562. 21 indexed citations
2.
Sanderlin, Edward J., et al.. (2020). The Proton-Sensing GPR4 Receptor Regulates Paracellular Gap Formation and Permeability of Vascular Endothelial Cells. iScience. 23(2). 100848–100848. 38 indexed citations
3.
Velcicky, Juraj, Rainer Wilcken, Simona Cotesta, et al.. (2020). Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure. Journal of Medicinal Chemistry. 63(17). 9856–9875. 24 indexed citations
4.
Velcicky, Juraj, Casey J. N. Mathison, V. I. Nikulin, et al.. (2019). Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors. ACS Medicinal Chemistry Letters. 10(6). 887–892. 9 indexed citations
5.
Sanderlin, Edward J., Mona A. Marie, Juraj Velcicky, Pius Loetscher, & Li V. Yang. (2019). Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model. European Journal of Pharmacology. 852. 218–230. 34 indexed citations
6.
Velcicky, Juraj, Ursula Bodendorf, Pascal Rigollier, et al.. (2018). Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. Journal of Medicinal Chemistry. 61(3). 865–880. 20 indexed citations
7.
Velcicky, Juraj, Achim Schlapbach, Richard Heng, et al.. (2018). Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure. ACS Medicinal Chemistry Letters. 9(4). 392–396. 15 indexed citations
8.
Miltz, Wolfgang, Juraj Velcicky, Janet Dawson, et al.. (2017). Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis. Bioorganic & Medicinal Chemistry. 25(16). 4512–4525. 22 indexed citations
9.
Hirschhäuser, Christoph, Juraj Velcicky, Jörg‐Martin Neudörfl, et al.. (2013). Nucleoside Analogues with a 1,3‐DieneFe(CO)3 Substructure: Stereoselective Synthesis, Configurational Assignment, and Apoptosis‐Inducing Activity. Chemistry - A European Journal. 19(39). 13017–13029. 22 indexed citations
10.
Révész, Láśzló, Achim Schlapbach, Reiner Aichholz, et al.. (2010). In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I. Bioorganic & Medicinal Chemistry Letters. 20(15). 4715–4718. 23 indexed citations
11.
Révész, Láśzló, Achim Schlapbach, Reiner Aichholz, et al.. (2010). In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Bioorganic & Medicinal Chemistry Letters. 20(15). 4719–4723. 27 indexed citations
12.
Velcicky, Juraj, et al.. (2010). Synthesis of 3-Chloro-4-fluoro-7,8-dihydro-6H-isoquinolin-5-one and Its Derivatives. Synlett. 2010(9). 1397–1401. 4 indexed citations
13.
Velcicky, Juraj, Roland Feifel, Stuart Hawtin, et al.. (2009). Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. Bioorganic & Medicinal Chemistry Letters. 20(3). 1293–1297. 35 indexed citations
14.
Schlapbach, Achim, Roland Feifel, Stuart Hawtin, et al.. (2008). Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity. Bioorganic & Medicinal Chemistry Letters. 18(23). 6142–6146. 35 indexed citations
15.
Elliott, Gregory I., et al.. (2005). Total Synthesis of (−)‐ and ent‐(+)‐Vindorosine: Tandem Intramolecular Diels–Alder/1,3‐Dipolar Cycloaddition of 1,3,4‐Oxadiazoles. Angewandte Chemie International Edition. 45(4). 620–622. 72 indexed citations
16.
Elliott, Gregory I., et al.. (2005). Total Synthesis of (−)‐ and ent‐(+)‐Vindorosine: Tandem Intramolecular Diels–Alder/1,3‐Dipolar Cycloaddition of 1,3,4‐Oxadiazoles. Angewandte Chemie. 118(4). 636–638. 13 indexed citations
17.
Choi, Younggi, Hayato Ishikawa, Juraj Velcicky, et al.. (2005). Total Synthesis of (−)- and ent-(+)-Vindoline. Organic Letters. 7(20). 4539–4542. 90 indexed citations
18.
Velcicky, Juraj, et al.. (2004). Iron‐Containing Nucleoside Analogues with Pronounced Apoptosis‐Inducing Activity. Angewandte Chemie International Edition. 43(13). 1731–1734. 75 indexed citations
19.
Velcicky, Juraj, et al.. (2004). Transition‐Metal‐Mediated Synthesis of Novel Carbocyclic Nucleoside Analogues with Antitumoral Activity. Chemistry - A European Journal. 10(20). 5087–5110. 38 indexed citations
20.
Velcicky, Juraj, Johann Lex, & Hans‐Günther Schmalz. (2002). An Efficient Organometallic Approach to New Carbocyclic Nucleoside Analogues. Organic Letters. 4(4). 565–568. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frederick W. Goldberg Breakdown of academic impact, for papers by Darren McKerrecher Breakdown of academic impact, for papers by Andrea M. Zuhl Breakdown of academic impact, for papers by Jaclyn L. Henderson Breakdown of academic impact, for papers by Anne Mengel Breakdown of academic impact, for papers by Jun‐ichi Haruta Breakdown of academic impact, for papers by Andrew Madin Breakdown of academic impact, for papers by Etienne J. Donckèle Breakdown of academic impact, for papers by Jenny Roy Breakdown of academic impact, for papers by G.M. Robertson
Rankless by CCL
2026